IRWD Ironwood Pharmaceuticals Inc
Price (delayed)
$1.44
Market cap
$233.01M
P/E Ratio
144
Dividend/share
N/A
EPS
$0.01
Enterprise value
$743.93M
Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the
Highlights
The EPS has surged by 150% since the previous quarter and by 100% year-on-year
The net income has soared by 136% from the previous quarter and by 100% YoY
Ironwood Pharmaceuticals's gross profit has decreased by 21% YoY and by 7% QoQ
IRWD's revenue is down by 21% YoY and by 7% QoQ
Key stats
What are the main financial stats of IRWD
Market
Valuations
Earnings
Shares outstanding
161.81M
Market cap
$233.01M
Enterprise value
$743.93M
Price to earnings (P/E)
144
Price to book (P/B)
N/A
Price to sales (P/S)
0.65
EV/EBIT
7.57
EV/EBITDA
7.42
EV/Sales
2.12
Revenue
$351.41M
Gross profit
$351.41M
Operating income
$93.12M
Net income
$880,000
EBIT
$98.23M
EBITDA
$100.24M
Free cash flow
$103.41M
Per share
Balance sheet
Liquidity
EPS
$0.01
EPS diluted
$0.01
Free cash flow per share
$0.65
Book value per share
-$1.88
Revenue per share
$2.21
TBVPS
$2.19
Total assets
$350.91M
Total liabilities
$652.24M
Debt
$599.48M
Equity
-$301.34M
Working capital
$143.52M
Debt to equity
-1.99
Current ratio
4.69
Quick ratio
4.39
Net debt/EBITDA
5.1
Margins
Efficiency
Dividend
EBITDA margin
28.5%
Gross margin
100%
Net margin
0.3%
Operating margin
26.5%
Return on assets
0.2%
Return on equity
N/A
Return on invested capital
11.8%
Return on capital employed
31.5%
Return on sales
28%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IRWD stock price
How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
2.13%
1 week
-1.37%
1 month
-10.56%
1 year
-82.48%
YTD
-67.49%
QTD
-2.04%
Financial performance
How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$351.41M
Gross profit
$351.41M
Operating income
$93.12M
Net income
$880,000
Gross margin
100%
Net margin
0.3%
IRWD's net margin has surged by 143% since the previous quarter and by 100% year-on-year
The net income has soared by 136% from the previous quarter and by 100% YoY
IRWD's operating margin has surged by 112% year-on-year
The operating income has soared by 110% YoY but it has decreased by 6% from the previous quarter
Growth
What is Ironwood Pharmaceuticals's growth rate over time
Valuation
What is Ironwood Pharmaceuticals stock price valuation
P/E
144
P/B
N/A
P/S
0.65
EV/EBIT
7.57
EV/EBITDA
7.42
EV/Sales
2.12
The EPS has surged by 150% since the previous quarter and by 100% year-on-year
The company's equity rose by 13% YoY and by 3.2% QoQ
IRWD's P/S is 84% below its 5-year quarterly average of 3.9 and 73% below its last 4 quarters average of 2.4
IRWD's revenue is down by 21% YoY and by 7% QoQ
Efficiency
How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's return on assets has surged by 133% QoQ and by 100% YoY
The return on sales has surged by 114% year-on-year
Ironwood Pharmaceuticals's ROIC has soared by 111% YoY but it has decreased by 7% from the previous quarter
Dividends
What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IRWD.
Financial health
How did Ironwood Pharmaceuticals financials performed over time
The total assets is 46% less than the total liabilities
The quick ratio has increased by 32% since the previous quarter
Ironwood Pharmaceuticals's current ratio has increased by 30% from the previous quarter
IRWD's debt is down by 16% year-on-year and by 2.5% since the previous quarter
The company's equity rose by 13% YoY and by 3.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.